Bcl-2 inhibitor abt-737 effectively targets leukemia-initiating cells with differential regulation of relevant genes leading to extended survival in a nras/bcl-2 mouse model of high risk-myelodysplastic syndrome
Petra Gorombei, Fabien Guidez, Saravanan Ganesan, Mathieu Chiquet, Andrea Pellagatti, Laure Goursaud, Nilgun Tekin, Stephanie Beurlet, Satyananda Patel, Laura Guerenne, Carole Le Pogam, Niclas Setterblad, Pierre de la Grange, Christophe Leboeuf, Anne Janin, Maria Elena Noguera, Laure Sarda-Mantel, Pascale Merlet, Jacqueline Boultwood, Marina KonoplevaMichael Andreeff, Robert West, Marika Pla, Lionel Adès, Pierre Fenaux, Patricia Krief, Christine Chomienne, Nader Omidvar, Rose Ann Padua
Dive into the research topics of 'Bcl-2 inhibitor abt-737 effectively targets leukemia-initiating cells with differential regulation of relevant genes leading to extended survival in a nras/bcl-2 mouse model of high risk-myelodysplastic syndrome'. Together they form a unique fingerprint.